Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Chris Lange | Sep 24, 2018 at 12:10 PM EDT

Kodiak Sciences Announces Potential Pricing for IPO

Clinical-stage biopharmaceutical company Kodiak Sciences expects to price 9 million shares for an initial public company valued up to more…

Jon C. Ogg | Sep 24, 2018 at 10:45 AM EDT

What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies…

Lee Jackson | Sep 24, 2018 at 10:25 AM EDT

Jefferies Biotech Growth Picks Have Big Upside Potential

Jefferies highlights the firm's top growth stocks to buy each week, and recently four top biotech stocks made the cut.…

Chris Lange | Sep 24, 2018 at 10:00 AM EDT

Why Amarin Shares Are Exploding

Amarin shares absolutely skyrocketed on Monday after the company announced topline results from the Vascepa cardiovascular (CV) outcomes trial, REDUCE-IT.…

Paul Ausick | Sep 22, 2018 at 9:17 AM EDT

Alzheimer’s, Dementia Will Hit Minority Groups Hardest

Changing U.S. demographics will change the proportion of Americans who suffer from Alzheimer's and other dementia-related diseases. The diseases are…

Chris Lange | Sep 21, 2018 at 11:50 AM EDT

What the FDA Has to Say About Acadia Pharma’s Parkinson’s Treatment

Acadia Pharmaceuticals shares popped after the company announced that the FDA completed a postmarketing review and issued a clear statement…

Jon C. Ogg | Sep 21, 2018 at 10:45 AM EDT

Why JPMorgan Is So Bullish on Novavax

Friday's trading session showed Novavax on the leaderboard after an analyst upgrade from JPMorgan.

Chris Lange | Sep 21, 2018 at 10:25 AM EDT

Can GTx Make It Past This Enobosarm Study?

GTx shares were absolutely crushed on Friday after the company announced results from its mid-stage trial in post-menopausal women with…

Lee Jackson | Sep 21, 2018 at 8:45 AM EDT

Stifel Has Red-Hot Biotech Stocks to Buy With Huge Upside Potential

A series of new Stifel research reports focus on three biotech companies that have upcoming clinical data that could prove…

Chris Lange | Sep 20, 2018 at 1:45 PM EDT

Elanco Explodes Into the Market in IPO

Eli Lilly spin-off Elanco Animal Health made a strong entrance to the market on Thursday.

Chris Lange | Sep 20, 2018 at 10:30 AM EDT

How Adverum Bio Is Winning With FDA Update

Adverum Biotechnologies shares made a handy gain on Thursday after the company announced a key update from the FDA.

Chris Lange | Sep 19, 2018 at 1:50 PM EDT

Should AbbVie Be More Concerned About Its California Case for Humira?

AbbVie shares took a dip on Wednesday after it was announced that the pharma giant would be facing a lawsuit…

Chris Lange | Sep 19, 2018 at 1:00 PM EDT

Clovis Finally Faces the Music for Fraudulent Lung Cancer Drug Results

Clovis shares might not be showing it now, but the company is facing some heat from the SEC over charges…

Chris Lange | Sep 18, 2018 at 11:55 AM EDT

Why Tilray Shares Are Getting Even Higher

Tilray continued its incredible rally with shares up massively on Tuesday after the U.S. Drug Enforcement Administration granted approval for…

Chris Lange | Sep 18, 2018 at 9:40 AM EDT

Why Viking Therapeutics Fatty Liver Study More Than Doubled Shares

Viking Therapeutics shares more than doubled on Tuesday after the company announced results from its mid-stage non-alcoholic fatty liver disease…

1 … 119 120 121 122 123 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Kodiak Sciences Announces Potential Pricing for IPO

What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

Jefferies Biotech Growth Picks Have Big Upside Potential

Why Amarin Shares Are Exploding

Alzheimer’s, Dementia Will Hit Minority Groups Hardest

What the FDA Has to Say About Acadia Pharma’s Parkinson’s Treatment

Why JPMorgan Is So Bullish on Novavax

Can GTx Make It Past This Enobosarm Study?

Stifel Has Red-Hot Biotech Stocks to Buy With Huge Upside Potential

Elanco Explodes Into the Market in IPO

How Adverum Bio Is Winning With FDA Update

Should AbbVie Be More Concerned About Its California Case for Humira?

Clovis Finally Faces the Music for Fraudulent Lung Cancer Drug Results

Why Tilray Shares Are Getting Even Higher

Why Viking Therapeutics Fatty Liver Study More Than Doubled Shares

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

‘Your Knowledge of Money and How It Works Is Nil’: Suze Orman to 62-Year-Old Who Nearly Locked His Wife Into $605 a Month

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

Health and Healthcare Articles

All Health and Healthcare Articles

Kodiak Sciences Announces Potential Pricing for IPO

What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

Jefferies Biotech Growth Picks Have Big Upside Potential

Why Amarin Shares Are Exploding

Alzheimer’s, Dementia Will Hit Minority Groups Hardest

What the FDA Has to Say About Acadia Pharma’s Parkinson’s Treatment

Why JPMorgan Is So Bullish on Novavax

Can GTx Make It Past This Enobosarm Study?

Stifel Has Red-Hot Biotech Stocks to Buy With Huge Upside Potential

Elanco Explodes Into the Market in IPO

How Adverum Bio Is Winning With FDA Update

Should AbbVie Be More Concerned About Its California Case for Humira?

Clovis Finally Faces the Music for Fraudulent Lung Cancer Drug Results

Why Tilray Shares Are Getting Even Higher

Why Viking Therapeutics Fatty Liver Study More Than Doubled Shares

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

‘Your Knowledge of Money and How It Works Is Nil’: Suze Orman to 62-Year-Old Who Nearly Locked His Wife Into $605 a Month

Featured Reads

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.